New FDA Approval: Deucravacitinib (Sotyktu), a First-In-Class Oral, Allosteric Tyrosine Kinase 2 Inhibitor

In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug.

This premium deep dive into deucravacitinib includes:

• the industry context

• the clinical data

• the target rationale

• the mechanism of action

• the drug’s origins

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.